1. Home
  2. SILO vs CERO Comparison

SILO vs CERO Comparison

Compare SILO & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SILO
  • CERO
  • Stock Information
  • Founded
  • SILO 2010
  • CERO 2017
  • Country
  • SILO United States
  • CERO United States
  • Employees
  • SILO N/A
  • CERO N/A
  • Industry
  • SILO Apparel
  • CERO
  • Sector
  • SILO Consumer Discretionary
  • CERO
  • Exchange
  • SILO Nasdaq
  • CERO Nasdaq
  • Market Cap
  • SILO 8.8M
  • CERO 8.4M
  • IPO Year
  • SILO N/A
  • CERO N/A
  • Fundamental
  • Price
  • SILO $1.72
  • CERO $1.93
  • Analyst Decision
  • SILO
  • CERO
  • Analyst Count
  • SILO 0
  • CERO 0
  • Target Price
  • SILO N/A
  • CERO N/A
  • AVG Volume (30 Days)
  • SILO 9.1M
  • CERO 1.3M
  • Earning Date
  • SILO 02-14-2025
  • CERO 02-20-2025
  • Dividend Yield
  • SILO N/A
  • CERO N/A
  • EPS Growth
  • SILO N/A
  • CERO N/A
  • EPS
  • SILO N/A
  • CERO N/A
  • Revenue
  • SILO $72,102.00
  • CERO N/A
  • Revenue This Year
  • SILO $1.86
  • CERO N/A
  • Revenue Next Year
  • SILO N/A
  • CERO N/A
  • P/E Ratio
  • SILO N/A
  • CERO N/A
  • Revenue Growth
  • SILO N/A
  • CERO N/A
  • 52 Week Low
  • SILO $0.77
  • CERO $1.76
  • 52 Week High
  • SILO $4.50
  • CERO $1,238.00
  • Technical
  • Relative Strength Index (RSI)
  • SILO 55.45
  • CERO 33.68
  • Support Level
  • SILO $1.50
  • CERO $1.76
  • Resistance Level
  • SILO $1.89
  • CERO $3.18
  • Average True Range (ATR)
  • SILO 0.20
  • CERO 0.40
  • MACD
  • SILO -0.05
  • CERO 0.28
  • Stochastic Oscillator
  • SILO 37.29
  • CERO 15.69

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

Share on Social Networks: